Is Unihealth Hosp overvalued or undervalued?

As of 17 June 2025, Unihealth Hospital's valuation grade has moved from fair to very attractive, indicating a significant improvement in its investment appeal. The company is currently assessed as undervalued. Key financial ratios include a PE ratio of 17.80, an EV to EBITDA of 13.85, and a PEG ratio of 0.38, all of which suggest that the stock is priced favorably compared to its earnings growth potential.
In comparison to its peers, Unihealth Hospital stands out with a much lower PE ratio than Max Healthcare, which has a PE of 104.87, and Apollo Hospitals at 69.68. This positions Unihealth as a more attractive investment relative to these competitors. Additionally, the company's recent stock performance has outpaced the Sensex, with a year-to-date return of 19.05% compared to the Sensex's 5.11%, reinforcing the notion that Unihealth is a compelling investment opportunity.